Alterity Therapeutics (ATHE) News Today $3.42 +0.06 (+1.79%) Closing price 01/17/2025 03:59 PM EasternExtended Trading$3.50 +0.08 (+2.19%) As of 08:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Alterity Therapeutics (NASDAQ:ATHE) & Incannex Healthcare (NASDAQ:IXHL) Head-To-Head ContrastJanuary 15, 2025 | americanbankingnews.comALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming MilestonesJanuary 9, 2025 | finanznachrichten.deAlterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming MilestonesJanuary 9, 2025 | globenewswire.comAlterity Therapeutics Limited (PRNAF)December 20, 2024 | nz.finance.yahoo.comMaxim Group Initiates Coverage of Alterity Therapeutics Limited - Depositary Receipt () (ATHE) with Buy RecommendationDecember 13, 2024 | msn.comAlterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System AtrophyDecember 4, 2024 | globenewswire.comAlterity Therapeutics announces change in company secretaryNovember 21, 2024 | investing.comAlterity Therapeutics Appoints Abby Macnish Niven as Company SecretaryNovember 19, 2024 | globenewswire.comAlterity Therapeutics announces presentation on bioMUSE studyNovember 13, 2024 | markets.businessinsider.comAlterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International SymposiumNovember 12, 2024 | globenewswire.comAlterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434November 6, 2024 | globenewswire.comAlterity Therapeutics reports cash balance of A$9.28M as of September 30October 31, 2024 | markets.businessinsider.comAppendix 4C – Q1 FY25 Quarterly Cash Flow ReportOctober 31, 2024 | globenewswire.comAlterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024October 14, 2024 | globenewswire.comAlterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience MeetingOctober 11, 2024 | globenewswire.comAlterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders®October 2, 2024 | globenewswire.comALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial OfficerSeptember 30, 2024 | finanznachrichten.deMarsh McLennan strikes $7.75 billion deal for McGriff Insurance ServicesSeptember 30, 2024 | ca.finance.yahoo.comAlterity Therapeutics Appoints Abby Macnish Niven as Chief Financial OfficerSeptember 30, 2024 | finance.yahoo.comAlterity Therapeutics Appoints Abby Macnish Niven as Chief Financial OfficerSeptember 30, 2024 | globenewswire.comAlterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson's Disease and Movement Disorders®September 23, 2024 | globenewswire.comAlterity Therapeutics Ltd (ATH)August 30, 2024 | investing.comAlterity Therapeutics Ltd (PBN.SG)August 17, 2024 | nz.finance.yahoo.comAlterity Therapeutics Ltd (PBN.HM)August 5, 2024 | finance.yahoo.comAppendix 4C – Q4 FY24 Quarterly Cash Flow ReportJuly 31, 2024 | globenewswire.comAlterity Therapeutics to Present at MST Financial WebinarJuly 24, 2024 | globenewswire.comAlterity Therapeutics: ATH434-202 Phase 2 Clinical Trial Shows Positive Data In MSAJuly 19, 2024 | markets.businessinsider.comAlterity stock climbs 8% on positive Phase 2 data for ATH434-202July 19, 2024 | msn.comAlterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System AtrophyJuly 17, 2024 | globenewswire.comAlterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System AtrophyJuly 17, 2024 | globenewswire.comAlterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences' WebinarJune 12, 2024 | globenewswire.comAlterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History StudyMay 29, 2024 | globenewswire.comAlterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third ReviewMay 8, 2024 | globenewswire.comAppendix 4C – Q3 FY24 Quarterly Cash Flow ReportApril 30, 2024 | globenewswire.comAlterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s AtaxiaApril 29, 2024 | finance.yahoo.comAlterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's AtaxiaApril 29, 2024 | globenewswire.comAlterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual MeetingApril 17, 2024 | finance.yahoo.comAlterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024April 10, 2024 | globenewswire.comAlterity Therapeutics Limited (ATHE)April 5, 2024 | finance.yahoo.comAlterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive RefundMarch 26, 2024 | globenewswire.comAlterity Therapeutics Ltd ADR ATHEMarch 24, 2024 | morningstar.comATHE Alterity Therapeutics LimitedMarch 22, 2024 | seekingalpha.comAlterity Therapeutics Ltd. ADRMarch 22, 2024 | wsj.comAlterity Therapeutics drops on capital raiseFebruary 23, 2024 | msn.comAlterity Therapeutics Stock (NASDAQ:ATHE), Short Interest ReportFebruary 22, 2024 | benzinga.comTrading was temporarily halted for "ATHE" at 05:02 PM with a stated reason of "News pending."February 21, 2024 | marketbeat.comAlterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual MeetingFebruary 20, 2024 | finance.yahoo.comAlterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual MeetingFebruary 20, 2024 | globenewswire.comAlterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This WeekJanuary 29, 2024 | finance.yahoo.comAlterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming MilestonesJanuary 22, 2024 | finance.yahoo.com Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter. Email Address ATHE Media Mentions By Week ATHE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATHE News Sentiment▼-0.500.49▲Average Medical News Sentiment ATHE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATHE Articles This Week▼10▲ATHE Articles Average Week Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ABOS News Today CRDL News Today LPTX News Today MGX News Today HLVX News Today ME News Today TARA News Today DBVT News Today ORMP News Today ALXO News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATHE) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
